R Gregory Bociek

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 3

Top Topics

Multidrug Resistant

Chronic Lymphocytic Leukemia

Mesenchymal Stem Cells

Top Venues

Cancer research communications

This page only lists publications with an associated author ORCID identifier.

Publications

Alexandria P Eiken, Audrey L Smith, Sydney A Skupa, Elizabeth Schmitz, Sandeep Rana, Yongseok Choi, Siddhartha Kumar, Jayapal Reddy Mallareddy, Aguirre A de Cubas, Akshay Krishna, Achyuth Kalluchi, M Jordan Rowley, Christopher R D'Angelo, Matthew A Lunning, R Gregory Bociek, Julie M Vose, Amarnath Natarajan, Dalia El-Gamal
Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects. Cancer research communications 4 (5) (2024)
Alexandria P Eiken, Audrey L Smith, Sydney A Skupa, Elizabeth Schmitz, Sandeep Rana, Yongseok Choi, Siddhartha Kumar, Jayapal Reddy Mallareddy, Aguirre A de Cubas, Akshay Krishna, Achyuth Kalluchi, M Jordan Rowley, Christopher R D'Angelo, Matthew A Lunning, R Gregory Bociek, Julie M Vose, Amarnath Natarajan, Dalia El-Gamal
Novel spirocyclic dimer, SpiD3, targets chronic lymphocytic leukemia survival pathways with potent preclinical effects. Cancer research communications (2024)
Alexandria P Eiken, Audrey L Smith, Sydney A Skupa, Elizabeth Schmitz, Sandeep Rana, Yongseok Choi, Siddhartha Kumar, Jayapal Reddy Mallareddy, Aguirre A de Cubas, Akshay Krishna, Achyuth Kalluchi, M Jordan Rowley, Christopher R D'Angelo, Matthew A Lunning, R Gregory Bociek, Julie M Vose, Amarnath Natarajan, Dalia El-Gamal
Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects. Cancer research communications 4 (5) (2024)